CervoMed (CRVO)’s Q4 Results Feature Advancements in Its Neflamapimod Program for Dementia Lewy Bodies (DLB)
On March 17, 2026, CervoMed Inc. (NASDAQ:CRVO) announced results for the fourth quarter and full year 2025.
Cervomed Inc. (CRVO)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Millennium Management Israel Englander | 60,268 | $476,117 | -16% | 0% |
| 2. | Citadel Investment Group Ken Griffin | 49,250 | $389,075 | +62% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $7.95 | 1,500 | $11,925.00 | 15,000 | 2025-11-18 | Filing | |
| $8.43 | 3,500 | $29,505.00 | 13,500 | 2025-11-17 | Filing | |
| $8.46 | 10,807 | $91,427.22 | 12,500 | 2025-11-17 | Filing | |
| $8.46 | 10,793 | $91,308.78 | 1,484,078 | 2025-11-17 | Filing | |
| $8.32 | 2,500 | $20,800.00 | 12,500 | 2025-11-18 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.00 | 36 | $0.00 | 840,451 | 2024-02-26 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 14,700 | $57,918 | 0.03% | |
| 2. | 0 | $0 | 0% | |
| 3. | 0 | $0 | 0% |
News See All
Top 10 Stocks Under $5 That Could Triple
At one end of the spectrum, until a few weeks ago, there was optimism about the broader market's performance this year.
CervoMed Strengthens Leadership with Technical Operations Hire to Advance Neflamapimod Toward Phase 3
CervoMed Inc. (NASDAQ:CRVO) is one of the best-performing NASDAQ stocks according to analysts. On June 10, CervoMed announced a significant addition to its senior leadership team. Dr.
12 Best Performing NASDAQ Stocks According to Analysts
On July 3, Dan Ives, the Global Head of Tech Research at Wedbush, appeared on CNBC to suggest that AI will fuel a multi-year tech rally. Ives stated that he believes they are only at the beginning of...
10 Best Short Squeeze Stocks to Buy According to Analysts
Stock market trading has an ever-changing environment. Short squeeze is among the few phenomena capable of capturing and holding the attention of such markets.
10 Best Short-Term Stocks To Buy Right Now
Thrilling highs, daunting lows, and the energized chase after the next big opportunity – this thoroughly defines the current stock market.
Why CervoMed (CRVO) Is Advancing Today
After meeting with CRVO's management and analyzing its recent drug trial results, Boral believes that the company can improve the performance of its neflamapimod drug by using a higher dose of 80 milligrams...